港股异动丨利好叠加，恒瑞医药继续涨超6%，3日累计反弹逾13%

Core Viewpoint - 恒瑞医药 continues its rebound, rising over 6% and accumulating a total increase of over 13% in three days, currently priced at 74.4 HKD with a total market capitalization of 494.1 billion HKD [1] Group 1: Clinical Trials and Drug Development - 恒瑞医药 announced the approval from the National Medical Products Administration for two drug clinical trial notifications, including HRS-8364 tablets for late-stage solid tumors, with no similar drugs approved in the domestic and international markets [1] - The cumulative R&D investment for the HRS-8364 project is approximately 21.65 million CNY [1] - The injectable drug 瑞康曲妥珠单抗 will also commence clinical trials for HER2-positive solid tumor patients [1] Group 2: Industry Recognition and Events - 恒瑞医药 has over 10 research projects selected for presentation at the upcoming ESMO Asia conference, scheduled from December 5 to 7 in Singapore, highlighting the company's research capabilities in oncology [1] - This participation reflects the influence of Chinese pharmaceutical innovation on the global academic stage [1]